Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 35

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 35
---
 to maintain adequate liquidity. Negative results from studies or trials, if any, or depressed prices of our Common Stock could impact our ability to raise additional financing. Raising additional equity capital is subject to market conditions that are not within our control.

   Net cash used in operating activities

Net cash used in operating activities
for the three months ended June 30, 2025 was $1,801, compared to $3,596 for the
three months ended June 30, 2025, a decrease of $1,795. The decrease in net
cash used in operating activities was primarily due to a $1,753 decrease in
research and development activities mainly due to completion of our GTx-104 pivotal
Phase 3 STRIVE-ON trial and changes in prepaid expenses of $292, offset in part
by a change in receivables of $ 220, and change in trade and other payables of
$203. 

   Net cash used in investing activities

   There were no investing activities for the three months ended June 30, 2025.  Net cash used in investing activities for the three months ended June 30, 2024 was from the purchase of short-term investments of $15.

   Net cash used in  financing activities

Net cash used in financing activities
for the three months ended June 30, 2025 was from the payment of stock issuance costs
in connection with the 2025 Private Placement. 
There were no financing activities for the three months ended June 30, 2024.

   2025 Private Placement

   In February 2025, we agreed to offer and sell in a private placement (the “2025 Private Placement”) an aggregate of 3,252,132 shares of Common Stock, at a purchase price of $3.395 per share of Common Stock (the “Shares”), and pre-funded warrants to purchase up to 1,166,160 shares of Common Stock, at a purchase price equal to the purchase price per Share less $0.0001 (the “2025 Pre-Funded Warrants”). Each 2025 Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share, is exercisable immediately and will expire once exercised in full. For each Share and 2025 Pre-Funded Warrant issued, we agreed to issue to each purchaser an accompanying common warrant to purchase shares of Common Stock (or 2025 Pre-F